Welcome to our dedicated page for Adaptive Biotechnologies SEC filings (Ticker: ADPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Adaptive Biotechnologies Corporation filings document financial results, governance matters, registered common stock, and material events for a commercial-stage biotechnology issuer. Recent 8-K reports furnish quarterly and annual operating results, press releases, investor presentation materials, and disclosures tied to the company’s MRD business and immune medicine platform.
The company’s proxy materials cover board and shareholder voting matters, executive compensation, equity awards, and related governance disclosures. Other filings identify ADPT common stock listed on Nasdaq and disclose material agreement activity connected to research and development collaborations, including immune medicine and TCR-antigen programs.
Adaptive Biotechnologies (ADPT) disclosed an insider transaction by its Chief Scientific Officer.
On 11/10/2025, Harlan S. Robins sold 10,000 shares of common stock at a weighted average price of $14.82, with trades ranging from $14.58 to $15.05, pursuant to a Rule 10b5-1 trading plan adopted on August 11, 2025. Following the sale, he beneficially owned 1,269,524 shares held directly.
Adaptive Biotechnologies (ADPT) insider activity: CEO and Chairman Chad M. Robins reported open-market sales of common stock executed under a Rule 10b5-1 trading plan adopted on August 11, 2025. On November 10, he sold 86,161 shares at a weighted average price of $14.73, followed by 1,237 shares at $14.57 on November 11, and 1,867 shares at $15.00 on November 12. After these transactions, he beneficially owned 2,869,975 shares directly. The prices reflect weighted averages across multiple trades within disclosed ranges.
Adaptive Biotechnologies (ADPT) reported stronger Q3 2025 results. Revenue rose to $93.973 million from $46.435 million a year ago, and the company posted net income of $9.545 million (basic and diluted EPS $0.06) versus a prior-year loss. Year-to-date revenue reached $205.295 million with a net loss of $45.878 million.
Growth reflected higher MRD service revenue and a spike in Immune Medicine collaboration revenue, including $33.742 million recognized from the Genentech collaboration. On August 13, 2025, the Genentech Agreement was terminated (effective February 9, 2026); remaining deferred revenue was recognized and the company is no longer eligible for future milestones or royalties.
Cash and cash equivalents were $55.034 million, with $157.735 million in short‑term marketable securities. Deferred revenue decreased to $42.543 million from $82.945 million at year‑end, reflecting revenue recognition. The revenue interest liability, net, was $131.838 million with an effective interest rate of 8.8%. Shares outstanding were 152,665,188 as of October 31, 2025.
Adaptive Biotechnologies (ADPT) furnished an 8-K announcing it issued a press release with financial results for the quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and incorporated by reference as stated therein.
The company notes the information provided under Item 2.02 and Exhibit 99.1 is furnished and shall not be deemed “filed” under the Exchange Act, nor incorporated into Securities Act or Exchange Act filings except by specific reference.
Adaptive Biotechnologies Corporation disclosed developments focused on its Immune Medicine initiatives. The filing notes work on TCR-antigen prediction models to enable new immunology applications and partnerships, and progress toward a pre-clinical data package for its lead T-cell depletion program in autoimmunity. The company also states a fiscal year 2025 Immune Medicine cash burn target of $25–$30 million. The filing references recognition of non-cash revenue from remaining amortization of cash consideration under an agreement. The document is dated August 18, 2025.